EARNEST Partners
AGIO icon

EARNEST Partners’s Agios Pharmaceuticals AGIO Stock Holding History

EARNEST Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8
Closed -$198 – 310
2023
Q3 		$198 Hold
8
– – ﹤0.01% 1149
2023
Q2 		$227 Hold
8
– – ﹤0.01% 1151
2023
Q1 		$184 Hold
8
– – ﹤0.01% 1154
2022
Q4 		$225 Hold
8
– – ﹤0.01% 1153
2022
Q3 		$0 Hold
8
– – ﹤0.01% 1121
2022
Q2 		$0 Hold
8
– – ﹤0.01% 1143
2022
Q1 		$0 Hold
8
– – ﹤0.01% 1150
2021
Q4 		$0 Hold
8
– – ﹤0.01% 1161
2021
Q3 		$0 Hold
8
– – ﹤0.01% 1164
2021
Q2 		$0 Hold
8
– – ﹤0.01% 1170
2021
Q1 		$0 Hold
8
– – ﹤0.01% 1174
2020
Q4 		$0 Hold
8
– – ﹤0.01% 1180
2020
Q3 		$0 Hold
8
– – ﹤0.01% 1160
2020
Q2 		$0 Hold
8
– – ﹤0.01% 1147
2020
Q1 		$0 Hold
8
– – ﹤0.01% 1109
2019
Q4 		$0 Hold
8
– – ﹤0.01% 1165
2019
Q3 		$0 Hold
8
– – ﹤0.01% 1156
2019
Q2 		$0 Hold
8
– – ﹤0.01% 1168
2019
Q1 		$1K Hold
8
– – ﹤0.01% 1077
2018
Q4 		$0 Hold
8
– – ﹤0.01% 1179
2018
Q3 		$1K Hold
8
– – ﹤0.01% 1089
2018
Q2 		$1K Hold
8
– – ﹤0.01% 1097
2018
Q1 		$1K Hold
8
– – ﹤0.01% 1071
2017
Q4 		$0 Buy
+8
New +$503 ﹤0.01% 1194
2017
Q1 		– Sell
-8
Closed – – 249
2016
Q4 		$0 Buy
+8
New +$420 ﹤0.01% 1142

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

EARNEST Partners's AGIO Position: Q4 2023 in Review

EARNEST Partners sold out of Agios Pharmaceuticals (AGIO) in Q4 2023, closing a stake of 8 shares — an estimated $198 sold.

EARNEST Partners first reported a position in AGIO in Q4 2016 and held it in 25 quarters. The position peaked at $1K in Q1 2019. 170 funds tracked by Wall St. Rank hold AGIO as of Q4 2023.

  • EARNEST Partners reported no remaining Agios Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • EARNEST Partners sold 8 Agios Pharmaceuticals shares in Q4 2023, an estimated $198.
  • EARNEST Partners first reported a position in Agios Pharmaceuticals in Q4 2016 and held it in 25 quarters.
  • EARNEST Partners's Agios Pharmaceuticals position peaked at $1K in Q1 2019.
  • 170 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.